Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Steminent Biotherapeutics's Dividend Yield % or its related term are showing as below:
ROCO:7729's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.325 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7729 vs VRTX, REGN, ALNY: Dividend Yield % Comparison
For the Biotechnology subindustry, Steminent Biotherapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steminent Biotherapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Steminent Biotherapeutics's Dividend Yield % falls into.
Steminent Biotherapeutics (ROCO:7729) has a Dividend Yield % of 0.00% as of Jul. 15, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Steminent Biotherapeutics and its competitors. According to the industry distribution chart, Steminent Biotherapeutics ranks #999999 out of 152 companies in the Biotechnology industry.
Is Steminent Biotherapeutics' Dividend Yield % too high?
Steminent Biotherapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Steminent Biotherapeutics ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Steminent Biotherapeutics ranks #999999 out of 152 companies for Dividend Yield %. This places Steminent Biotherapeutics in the lower half of its industry. The industry median Dividend Yield % is 1.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.33, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Steminent Biotherapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steminent Biotherapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Dividend Yield % is 0.00% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score
Get the complete analysis for ROCO:7729
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7729 has been successfully added to your 
